-
公开(公告)号：US20150299323A1
公开(公告)日：2015-10-22
申请号：US14597262
申请日：2015-01-15
Applicant: BIOGEN MA INC.
Inventor： Michael Karpusas , Paul D. Lyne , Ellen A. Garber Stark , Jose William Saldanha
IPC: C07K16/28
CPC classification number: C07K16/2842 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , Y02A90/26
Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
-
公开(公告)号：US20200262895A1
公开(公告)日：2020-08-20
申请号：US16580152
申请日：2019-09-24
Applicant: Biogen MA Inc. , Biogen International Neuroscience GmbH
Inventor： Paul H. Weinreb , Feng Chen , Ellen A. Garber Stark , Jan Grimm , Fabio Montrasio
Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
-
公开(公告)号：US10336826B2
公开(公告)日：2019-07-02
申请号：US15470442
申请日：2017-03-27
Applicant: BIOGEN MA INC.
Inventor： Michael Karpusas , Paul D. Lyne , Ellen A. Garber Stark , Jose William Saldanha
IPC: A61K39/395 , C07K16/28 , A61K39/00
Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
-
公开(公告)号：US20170335000A1
公开(公告)日：2017-11-23
申请号：US15470442
申请日：2017-03-27
Applicant: BIOGEN MA INC.
Inventor： Michael Karpusas , Paul D. Lyne , Ellen A. Garber Stark , Jose William Saldanha
CPC classification number: C07K16/2842 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , Y02A90/26
Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
-
公开(公告)号：US20210395360A1
公开(公告)日：2021-12-23
申请号：US17217263
申请日：2021-03-30
Applicant: Biogen MA Inc.
Inventor： Sha Mi , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber Stark , Steven D. Miklasz , Christilyn Graff
IPC: C07K16/28
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
-
Patent Agency Ranking
公开(公告)号：US20190169274A1
公开(公告)日：2019-06-06
申请号：US16020346
申请日：2018-06-27
Applicant: Biogen MA Inc. , Biogen International Neuroscience GmbH
Inventor： Paul H. Weinreb , Feng Chen , Ellen A. Garber Stark , Jan Grimm , Fabio Montrasio
Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
-
公开(公告)号：US09902775B2
公开(公告)日：2018-02-27
申请号：US14649297
申请日：2013-12-10
Applicant: Biogen MA Inc.
CPC classification number: C07K16/2851 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
-
公开(公告)号：US20170037126A1
公开(公告)日：2017-02-09
申请号：US15214818
申请日：2016-07-20
Applicant: Biogen MA Inc.
Inventor： Sha Mi , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber Stark , Steven D. Miklasz , Christilyn Graff
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。
-
公开(公告)号：US20200317775A1
公开(公告)日：2020-10-08
申请号：US16789738
申请日：2020-02-13
Applicant: Biogen MA Inc.
Inventor： Sha Mi , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber Stark , Steven D. Miklasz , Christilyn Graff
IPC: C07K16/28
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
-
公开(公告)号：US20190161546A1
公开(公告)日：2019-05-30
申请号：US16018819
申请日：2018-06-26
Applicant: Biogen MA Inc.
Inventor： Sha Mi , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber Stark , Steven D. Miklasz , Christilyn Graff
IPC: C07K16/28
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.036 seconds)
